Abstract
Public health authorities face the issue of optimal vaccine distribution during spread of pandemics. In this paper, we study the optimal way to distribute a finite stock of COVID-19 doses between first or second doses for unvaccinated individuals and third doses (booster shots) for fully vaccinated individuals. We introduce a novel compartmental model that accommodates for vaccinated populations. This Booster model is implemented to simulate two prototypes of populations: one with a highly infected and highly vaccinated proportion, and another with a low infected and vaccinated percentage. We namely use sample data from Russia and Djibouti respectively.
Our findings show that, to minimize the deaths for the first type of populations, around one quarter of the vaccines should be employed as booster shots and the rest as first and second doses. On the other hand, the second type of populations can minimize their number of deaths by mainly focusing on administering the initial two doses, rather than giving any booster shots. The novel Booster model allows us to study the effect of the third dose on a community and provides a useful tool to draw public policies on the distribution of vaccines during pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
